Buscar
25/10/2024
Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis
Martinez-Molina, C, Tey, JMG, Ruiz-Ramos, J, Feliu, A, Puig-Campmany, M, Vidal, S, Corominas, H. Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis. MEDICINA CLINICA. 2024; 163(8)DOI:10.1016/j.medcli.2024.05.007. PMID:39003114. IF:2.100(Q2/3D).
23/10/2024
Transforming respiratory diseases management: a CMO-based hospital pharmaceutical care model
Zarate-Tamames, B, Garin, N, Calvin-Lamas, M, Jornet, S, Martinez-Simon, JJ, Garcia-Gil, S, Garcia-Rebolledo, EM, Morillo-Verdugo, R. Transforming respiratory diseases management: a CMO-based hospital pharmaceutical care model. Frontiers in Pharmacology. 2024; 15DOI:10.3389/fphar.2024.1461473. PMID:39512818. IF:4.800(Q1/2D).
01/10/2024
DEVELOPMENT AND CLINICAL VALIDATION OF LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY FOR INDIVIDUALIZED RUXOLITINIB ADJUSTMENT IN FUTURE CASES OF STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE
Redondo, S, Costa, M, Moreno-Martinez, ME, Riba, M, Aso, O, Iranzo, E, Esquirol, A, Sierra, J, Briones, J, Martino, R, Zapico, E, Garcia-Cadenas, I. DEVELOPMENT AND CLINICAL VALIDATION OF LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY FOR INDIVIDUALIZED RUXOLITINIB ADJUSTMENT IN FUTURE CASES OF STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
EFFICACY AND SAFETY OF REDUCED-DOSES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PERIPHERAL BLOOD STEM CELL TRANSPLANTATION OUTSIDE THE HAPLOIDENTICAL SETTING
Redondo, S, Arrufat, A, Esquirol, A, Saavedra, S, Arguello-Tomas, M, Caballero, AC, O ate, G, Garrido, A, Lopez, J, Miqueleiz, S, Portos, JM, Iranzo, E, Moreno-Martinez, ME, Riba, M, Sierra, J, Briones, J, Garc a-Cadenas, I, Martino, R. EFFICACY AND SAFETY OF REDUCED-DOSES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PERIPHERAL BLOOD STEM CELL TRANSPLANTATION OUTSIDE THE HAPLOIDENTICAL SETTING. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
EVALUATION OF MENTAL HEALTH THROUGH AN EHEALTH PLATFORM IN THE MANAGEMENT OF ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS (MYMEDULA STUDY): DESCRIPTIVE ANALYSIS
Tobajas, E, Carretero, G, De Dios, A, Redondo, S, Vallv , M, Esquirol, A, Aso, O, Triquell, M, Moreno-Martinez, ME, Riba, M, Blasco, A, Martino, R, Gomis-Pastor, M, Garc a-Cadenas, I. EVALUATION OF MENTAL HEALTH THROUGH AN EHEALTH PLATFORM IN THE MANAGEMENT OF ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS (MYMEDULA STUDY): DESCRIPTIVE ANALYSIS. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
MOBILE HEALTH IN THE MANAGEMENT OF ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS (MY-MEDULA STUDY): PRELIMINARY RESULTS OF THE CLINICAL TRIAL
Redondo, S, De Dios, A, Vallve, M, Real, J, Triquell, M, Aso, O, Esquirol, A, Moreno-Martinez, M, Riba, M, Ruiz, J, Tobajas, E, Sierra, J, Briones, J, Martino, R, Gomis-Pastor, M, Garcia-Cadenas, I. MOBILE HEALTH IN THE MANAGEMENT OF ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS (MY-MEDULA STUDY): PRELIMINARY RESULTS OF THE CLINICAL TRIAL. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).